Pages that link to "Q34440364"
Jump to navigation
Jump to search
The following pages link to IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma (Q34440364):
Displaying 50 items.
- STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors (Q22010908) (← links)
- Monoclonal antibodies (Q24535231) (← links)
- Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies (Q24605057) (← links)
- Rituximab: mechanism of action (Q24607358) (← links)
- The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia (Q24617708) (← links)
- Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance (Q24644883) (← links)
- B cells as a therapeutic target in autoimmune disease (Q24804504) (← links)
- Characterization of lymphocyte populations in nonspecific interstitial pneumonia (Q24815753) (← links)
- Recent advances in the field of anti-cancer immunotherapy (Q26775602) (← links)
- Novel immunotherapies in lymphoid malignancies (Q26777394) (← links)
- Targeted Therapies in Adult B-Cell Malignancies (Q26783195) (← links)
- Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics (Q26784480) (← links)
- Hepatitis B virus reactivation with a rituximab-containing regimen (Q26785963) (← links)
- Hepatitis B virus reactivation with rituximab-containing regimen (Q26830484) (← links)
- Novel immunotherapies for hematologic malignancies (Q27004436) (← links)
- Biologics in dermatology: an integrated review (Q27004638) (← links)
- Evaluation of current cancer immunotherapy: hemato-oncology (Q27006179) (← links)
- Immunotherapy strategies for multiple myeloma: the present and the future (Q27021939) (← links)
- Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer (Q28077270) (← links)
- Are BiTEs the "missing link" in cancer therapy? (Q28083907) (← links)
- Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development (Q28084276) (← links)
- A pretargeting system for tumor PET imaging and radioimmunotherapy (Q28087820) (← links)
- Harnessing the Microbiome to Enhance Cancer Immunotherapy (Q28088598) (← links)
- Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma (Q30278460) (← links)
- Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods. (Q30363975) (← links)
- Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host (Q30395200) (← links)
- Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma (Q30419228) (← links)
- Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients (Q30421637) (← links)
- Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia (Q30436996) (← links)
- Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. (Q30764873) (← links)
- Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors (Q30847784) (← links)
- Recombinant antibodies for the diagnosis and treatment of cancer (Q31166188) (← links)
- The potential effect of statins on rituximab immunotherapy (Q33325581) (← links)
- Achieving optimal outcomes in chronic lymphocytic leukaemia (Q33337399) (← links)
- Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome (Q33358261) (← links)
- Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy (Q33360327) (← links)
- Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study (Q33363695) (← links)
- Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura (Q33369574) (← links)
- Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment (Q33372069) (← links)
- The potential utility of B cell-directed biologic therapy in autoimmune diseases (Q33377109) (← links)
- Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma (Q33381780) (← links)
- Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases (Q33405115) (← links)
- Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab (Q33405150) (← links)
- Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up. (Q33415094) (← links)
- A general process for the development of peptide-based immunoassays for monoclonal antibodies (Q33525284) (← links)
- Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma (Q33599174) (← links)
- Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker (Q33640235) (← links)
- Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. (Q33668990) (← links)
- Non-Hodgkin's lymphoma in the elderly: a guide to drug treatment (Q33688805) (← links)
- Rituximab (Q33706729) (← links)